<DOC>
	<DOC>NCT02129205</DOC>
	<brief_summary>To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.</brief_summary>
	<brief_title>A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available Previously treated metastatic triple negative breast cancer that expresses Notch3 with at least one measurable lesion Adequate bone marrow, renal and liver function Major surgery, radiation therapy or systemic anticancer therapy within 4 weeks of starting study treatment Patients with known symptomatic brain metastases requiring steroids Prior treatment with a compound of the same mechanism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>solid tumors</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>PF-06650808</keyword>
	<keyword>Phase 1</keyword>
</DOC>